Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis

Yun-Jung Choi, Yun-Jung Choi

Abstract

Objectives: This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patients taking atypical antipsychotics.

Methods: Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis.

Results: Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric evaluations did not show statistically significant changes between treatment groups and placebo groups except topiramate adjunctive treatments. Adverse effects regarding adjunctive therapies were tolerable and showed statistically no significances compared to control groups.

Conclusion: Though having several reports related to exacerbation of psychiatric symptoms, topiramate and aripiprazole are more efficacious than other medications in regard to weight reduction and less burden of critical adverse effects as well as being beneficial for clinical improvement.

Figures

Figure 1
Figure 1
The trial selection process for inclusion.

References

    1. Lévy E., Agbokou C., Ferreri F., Chouinard G., Margolese H. C. Topiramate—induced weight loss in schizophrenia: a retrospective case series study. Canadian Journal of Clinical Pharmacology. 2007;14(2):e234–e239.
    1. Kroeze W. K., Hufeisen S. J., Popadak B. A., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526. doi: 10.1038/sj.npp.1300027.
    1. Templeman L. A., Reynolds G. P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics. 2005;15(4):195–200.
    1. Maayan L., Vakhrusheva J., Correll C. U. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520–1530. doi: 10.1038/npp.2010.21.
    1. Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry. 2001;46(6):549–555.
    1. Muscatello M., Bruno A., Pandolfo G., et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Journal of Psychopharmacology. 2011;25(5):667–674. doi: 10.1177/0269881110372548.
    1. Henderson D. C., Fan X., Copeland P. M., et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. The American Journal of Psychiatry. 2005;162(5):954–962. doi: 10.1176/appi.ajp.162.5.954.
    1. Fleischhacker W. W., Heikkinen M. E., Olié J.-P., et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2010;13(8):1115–1125. doi: 10.1017/s1461145710000490.
    1. Narula P. K., Rehan H. S., Unni K. E. S., Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research. 2010;118(1–3):218–223. doi: 10.1016/j.schres.2010.02.001.
    1. Afshar H., Roohafza H., Mousavi G., et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology. 2009;23(2):157–162. doi: 10.1177/0269881108089816.
    1. Baptista T., Uzcátegui E., Rangel N., et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Research. 2008;159(1-2):250–253. doi: 10.1016/j.psychres.2008.01.011.
    1. Wu R.-R., Zhao J.-P., Guo X.-F., et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. The American Journal of Psychiatry. 2008;165(3):352–358. doi: 10.1176/appi.ajp.2007.07010079.
    1. Baptista T., Rangel N., Fernández V., et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophrenia Research. 2007;93(1–3):99–108. doi: 10.1016/j.schres.2007.03.029.
    1. Henderson D. C., Fan X., Copeland P. M., et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatrica Scandinavica. 2007;115(2):101–105. doi: 10.1111/j.1600-0447.2006.00855.x.
    1. Poyurovsky M., Fuchs C., Pashinian A., et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology. 2007;192(3):441–448. doi: 10.1007/s00213-007-0731-1.
    1. Baptista T., Martínez J., Lacruz A., et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. 2006;51(3):192–196.
    1. Poyurovsky M., Tal V., Maayan R., Gil-Ad I., Fuchs C., Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology. 2004;14(4):332–336. doi: 10.1016/j.euroneuro.2003.10.004.
    1. Cavazzoni P., Tanaka Y., Roychowdhury S. M., Breier A., Allison D. B. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. European Neuropsychopharmacology. 2003;13(2):81–85. doi: 10.1016/s0924-977x(02)00127-x.
    1. Poyurovsky M., Isaacs I., Fuchs C., et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry. 2003;160(2):297–302. doi: 10.1176/appi.ajp.160.2.297.
    1. Poyurovsky M., Pashinian A., Gil-Ad I., et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. The American Journal of Psychiatry. 2002;159(6):1058–1060. doi: 10.1176/appi.ajp.159.6.1058.
    1. Bertani A., Perna G., Migliarese G., et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2004;37(5):206–210. doi: 10.1055/s-2004-832593.
    1. Lu T. Y.-T., Kupa A., Easterbrook G., Mangoni A. A. Profound weight loss associated with reboxetine use in a 44-year-old woman. British Journal of Clinical Pharmacology. 2005;60(2):218–220. doi: 10.1111/j.1365-2125.2005.02407.x.
    1. Poyurovsky M., Faragian S., Fuchs C., Pashinian A. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. The Israel Journal of Psychiatry and Related Sciences. 2009;46(3):213–220.
    1. Radulovic L., Weiden P., Allison D. B. A double-blind, placebocontrolled trial of adjunctive sibutramine for obesity in patients with schizophrenia. Proceedings of the Meeting of the New Clinical Drug Evaluation Unit (NCDEU '02); 2002; Rockville, Md, USA. pp. 1–15.
    1. Scheen A. J. Sibutramine on cardiovascular outcome. Diabetes Care. 2011;34(2):S114–S119. doi: 10.2337/dc11-s205.
    1. Praharaj S. K., Jana A. K., Goyal N., Sinha V. K. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. British Journal of Clinical Pharmacology. 2011;71(3):377–382. doi: 10.1111/j.1365-2125.2010.03783.x.
    1. Kolotkin R. L., Corey-Lisle P. K., Crosby R. D., Kan H. J., McQuade R. D. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European Psychiatry. 2008;23(8):561–566. doi: 10.1016/j.eurpsy.2008.01.1421.
    1. Newcomer J. W., Campos J. A., Marcus R. N., et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of Clinical Psychiatry. 2008;69(7):1046–1056.
    1. Karunakaran K., Tungaraza T. E., Harborne G. C. Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? Journal of Psychopharmacology. 2007;21(4):453–456. doi: 10.1177/0269881106068289.
    1. Henderson D. C., Fan X., Copeland P. M., et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology. 2009;29(2):165–169. doi: 10.1097/jcp.0b013e31819a8dbe.
    1. Ben-Menachem E., Axelsen M., Johanson E. H., Stagge A., Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity Research. 2003;11(4):556–562.
    1. Gobbi G., Gaudreau P.-O., Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. Journal of Clinical Psychopharmacology. 2006;26(5):467–473. doi: 10.1097/01.jcp.0000237945.35022.45.
    1. Hahn M. K., Remington G., Bois D., Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Journal of Clinical Psychopharmacology. 2010;30(6):706–710. doi: 10.1097/jcp.0b013e3181fab67d.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe